At a glance
- Originator Aventis
- Class Antithrombotics; Small molecules
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 14 Aug 2001 New profile
- 14 Aug 2001 Preclinical development for Thrombosis in Germany (PO)